Correlation between severity of myelosuppression caused by piperacillin-tazobactam and factors: Analysis through a multivariate ordered logistic regression mode.

AIMS: To explore the factors influencing the severity of piperacillin-tazobactam-associated myelosuppression and the time of symptom onset and to provide a basis for clinical risk prevention and control. METHODS: Based on the electronic database and data from a city's adverse drug reaction monitoring system in the past 10 years, 115 patients with piperacillin-tazobactam-induced myelosuppression were included. Multivariate ordered logistic regression models were used to analyse the factors affecting severity and time to symptom onset. RESULTS: Concomitant medication significantly increased the risk of myelosuppression severity (OR = 3.95, p < 0.001). Male (OR = 4.03, p = 0.02), past medical history (OR = 4.25, p < 0.01) and prolonged duration of medication (OR = 1.60, p < 0.0001) accelerated symptom onset. Laboratory indices showed a significant decrease in leucocytes (2.2 × 109/L vs. 9.1 × 109/L) and platelets (25.5 × 109/L vs. 222.5 × 109/L) after medication (p < 0.001). Symptomatic improvement was observed after discontinuation of the medication in 80.0% of the patients, but prolongation of the original course of the disease due to myelosuppression was observed in 24.3% of the patients. CONCLUSION: Concomitant medication, especially multiple medication, is a key risk factor for the severity of myelosuppression, and early monitoring needs to be strengthened in males, those with past medical history and long-term medication users. This study provides data support for individualized medication regimens and risk warnings.